Float Short %

21.83

Margin Of Safety %

-21

Put/Call OI Ratio

4.11

EPS Next Q Diff

EPS Last/This Y

0.72

EPS This/Next Y

-0.54

Price

32.65

Target Price

66.52

Analyst Recom

1.41

Performance Q

-14.14

Upside

-123.1%

Beta

0.77

Ticker: IMCR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	IMCR	35.2	2.77	0.00	7134
2026-01-26	IMCR	35.14	2.77	0.00	7137
2026-01-27	IMCR	35.05	2.76	0.00	7138
2026-01-28	IMCR	33.11	2.75	0.00	7148
2026-01-29	IMCR	33.03	2.76	0.00	7143
2026-01-30	IMCR	32.57	2.76	0.00	7143
2026-02-02	IMCR	33.05	2.76	0.99	7141
2026-02-03	IMCR	32.02	2.52	0.00	7743
2026-02-04	IMCR	31.51	2.17	0.19	8100
2026-02-05	IMCR	30.92	2.20	0.13	8116
2026-02-06	IMCR	32.05	2.20	0.00	8123
2026-02-09	IMCR	33.23	2.19	0.00	8126
2026-02-10	IMCR	32.8	2.20	0.00	8125
2026-02-11	IMCR	33.09	2.20	0.00	8125
2026-02-12	IMCR	31.88	2.19	0.00	8126
2026-02-13	IMCR	32.33	2.19	156.50	8126
2026-02-17	IMCR	32.31	2.19	156.50	8126
2026-02-18	IMCR	32.38	2.19	156.50	8126
2026-02-20	IMCR	32.66	4.11	3568.50	13016
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	IMCR	35.12	60.0	-111.7	-0.30
2026-01-26	IMCR	35.08	60.0	-111.4	-0.30
2026-01-27	IMCR	35.05	60.0	-111.4	-0.30
2026-01-28	IMCR	33.14	60.0	-102.5	-0.30
2026-01-29	IMCR	33.03	60.0	-111.1	-0.30
2026-01-30	IMCR	32.57	60.0	-109.5	-0.30
2026-02-02	IMCR	33.08	60.0	-114.7	-0.30
2026-02-03	IMCR	32.02	60.0	-106.2	-0.30
2026-02-04	IMCR	31.56	60.0	-109.4	-0.30
2026-02-05	IMCR	31.00	60.0	-109.4	-0.30
2026-02-06	IMCR	32.06	60.0	-118.7	-0.30
2026-02-09	IMCR	33.26	57.5	-119.2	-0.30
2026-02-10	IMCR	32.80	57.5	-110.2	-0.30
2026-02-11	IMCR	33.00	57.5	-113.5	-0.30
2026-02-12	IMCR	31.88	57.5	-107.1	-0.30
2026-02-13	IMCR	32.24	57.5	-114.6	-0.30
2026-02-17	IMCR	32.42	57.5	-113.4	-0.30
2026-02-18	IMCR	32.51	57.5	-113.6	-0.30
2026-02-19	IMCR	33.19	57.5	-	-0.30
2026-02-20	IMCR	32.65	57.5	-	-0.30
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	IMCR	-40.40	2.63	19.01
2026-01-26	IMCR	-40.40	2.52	19.01
2026-01-27	IMCR	-40.40	2.52	19.01
2026-01-28	IMCR	-40.40	2.52	20.00
2026-01-29	IMCR	-40.40	2.52	20.00
2026-01-30	IMCR	-40.40	2.52	20.00
2026-02-02	IMCR	-40.40	2.52	20.00
2026-02-03	IMCR	-40.40	2.52	20.00
2026-02-04	IMCR	-40.40	2.52	20.00
2026-02-05	IMCR	-40.40	2.52	20.00
2026-02-06	IMCR	-40.40	2.52	20.00
2026-02-10	IMCR	-40.40	3.06	20.00
2026-02-11	IMCR	-40.40	3.06	21.83
2026-02-12	IMCR	-40.40	3.06	21.83
2026-02-13	IMCR	-40.40	3.06	21.83
2026-02-17	IMCR	-40.40	5.66	21.83
2026-02-18	IMCR	-40.40	5.66	21.83
2026-02-19	IMCR	-42.12	5.66	21.83
2026-02-20	IMCR	-42.12	5.66	21.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.13

Insider Transactions

-42.12

Institutional Transactions

5.66

Beta

0.77

Average Sales Estimate Current Quarter

107

Average Sales Estimate Next Quarter

108

Fair Value

25.81

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

57.6

Max Drawdown 5-Year %

-67.4

Target Price

66.52

P/E

Forward P/E

PEG

P/S

4.34

P/B

4.18

P/Free Cash Flow

576.7

EPS

-0.58

Average EPS Est. Cur. Y

-0.3

EPS Next Y. (Est.)

-0.84

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.67

Relative Volume

1.14

Return on Equity vs Sector %

-36.4

Return on Equity vs Industry %

-18.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Immunocore Holdings plc

Sector: Healthcare

Industry: Biotechnology

Employees: 493

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today

news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance

stock history IMCR – Immunocore Holdings plc ADR invest stock market

stock prices IMCR premarket after hours

ticker IMCR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: IMCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y